Preparation method and application of nano material aiming at diabetes mellitus complicated with colorectal cancer

By preparing targeted, lowering glycemic and drug-loading nanomaterials PDGFB-LFPHG, the targets discovered by proteomics technology and nanotechnology were combined to solve the problem that diabetes combined with colorectal cancer is difficult to achieve precise treatment, and efficient anti-aging Tumor effect.

CN118903454APending Publication Date: 2024-11-08BINZHOU MEDICAL COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411042476.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-08

Smart Images

  • Figure CN118903454A_ABST
    Figure CN118903454A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a nano material aiming at diabetes mellitus complicated with colorectal cancer, and relates to the technical field of biomedical materials.According to the method, a new target spot of diabetes mellitus complicated with colorectal cancer is found through proteomics, and then a sensitive drug homoharringtonine is found according to the characteristics of the target spot; then synthesizing a hydrophilic ultra-small iron-platinum nano-alloy; and finally preparing the nano-material PDGFB-LFPHG of the iron-platinum nano-alloy, homoharringtonine and glucose oxidase which are entrapped by lipidosome coupled with a B chain of the platelet-derived growth factor. The nanometer material PDGFB-LFPHG, which is prepared by the method provided by the invention, has the advantages of targeting, blood glucose reduction, drug loading and high efficiency and aims at the diabetes mellitus complicated with the colorectal cancer, can realize accurate targeting, safe and effective tumor treatment, and realizes customized and personalized treatment aiming at the diabetes mellitus complicated with the colorectal cancer; the problem that accurate treatment of diabetes combined with colorectal cancer cannot be achieved is effectively solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical materials, and in particular to a preparation method and application of a nanomaterial for diabetes combined with colorectal cancer. Background Art

[0002] Globally, colorectal cancer is the third most common malignant tumor in terms of incidence and the second most common malignant tumor in terms of mortality. It is also the most common malignant tumor of the digestive system. Compared with the general population, patients with type 2 diabetes have a higher risk of colorectal cancer. Compared with patients without diabetes, patients with colorectal cancer who have diabetes have a higher all-cause mortality rate, which is an independent factor affecting the prognosis of colorectal cancer. The molecular mechanism of diabetes and colorectal cancer has not yet been fully elucidated. Therefore, in-depth understanding of the potential mechanisms of diabetes and colorectal cancer, discovery of effective therapeutic targets, and application of specific targets are the basis for achieving precise diagnosis and treatment. Summary of the invention

[0003] In view of the above-mentioned deficiencies in the prior art, the present invention provides a method for preparing and applying a nanomaterial for diabetes combined with colorectal cancer. By this method, a nanomaterial for diabetes combined with colorectal cancer is prepared, which has the functions of targeting, hypoglycemic, drug loading and high efficiency. The nanomaterial can achieve precise targeted, safe and effective tumor treatment, and effectively solves the problem that precise treatment of diabetes combined with colorectal cancer cannot be achieved.

[0004] To achieve the above-mentioned purpose, the technical solution adopted by the present invention to solve the technical problem is: to provide a method for preparing a nanomaterial for diabetes combined with colorectal cancer, comprising the following steps:

[0005] S1, dissolving hexadecanediol and platinum acetylacetonate in dibenzyl ether, heating under nitrogen protection, then adding oleic acid and oleylamine and keeping warm to obtain a mixed solution 1;

[0006] S2, adding oleic acid, oleylamine and dinonyl iron to the mixed solution 1 obtained in step S1, continuing to heat, cooling to room temperature after reflux and washing, to obtain a hydrophobic ultra-small iron-platinum nanoalloy;

[0007] S3, dispersing the hydrophobic ultra-small iron-platinum nanoalloy obtained in step S2 in a n-hexane solution to obtain a mixed solution II, then adding a solution of tetrafluoroboron nitrite in N,N-dimethylamide, shaking until a two-phase layer appears on the liquid surface, removing the upper solution, and then adding dithiothiobutyric acid, shaking, washing and centrifuging to obtain a hydrophilic ultra-small iron-platinum nanoalloy;

[0008] S4, dissolving the platelet-derived growth factor B chain cyclic peptide in dimethyl sulfoxide, then adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and N-hydroxysuccinimide and stirring, then adding amino-containing polyethylene glycol and continuing to stir, removing impurities, and obtaining polyethylene glycol-modified platelet-derived growth factor B chain;

[0009] S5, dissolving homoharringtonine, soybean lecithin, cholesterol, distearoyl phosphatidylethanolamine and the polyethylene glycol-modified platelet-derived growth factor B chain obtained in step S4 in chloroform, and removing the organic solvent after rotary evaporation to obtain a platelet-derived growth factor B chain-targeted liposome membrane;

[0010] S6. Dissolve glucose oxidase and the hydrophilic ultrasmall iron-platinum nanoalloy obtained in step S3 in deionized water to obtain mixed solution three, then add the mixed solution three to the platelet-derived growth factor B chain-targeted liposome membrane obtained in step S5, and after water bath sonication, obtain a nanoliposome initial solution, extrude the solution, and freeze-dry to obtain a nanomaterial (PDGFB-LFPHG).

[0011] Furthermore, in step S1, the mass volume ratio of hexadecanediol, platinum acetylacetonate, dibenzyl ether, oleic acid and oleylamine is 0.1-0.3 g:0.05-0.15 g:10-30 mL:150-200 μL:150-200 μL.

[0012] Furthermore, the mass volume ratio of hexadecanediol, platinum acetylacetonate, dibenzyl ether, oleic acid and oleylamine is 0.2 g:0.1 g:20 mL:170 μL:170 μL.

[0013] Further, heating is performed to 90-110°C.

[0014] Furthermore, the mixture was heated to 100°C.

[0015] Further, keep warm for 25-35 minutes.

[0016] Further, keep warm for 30 minutes.

[0017] Furthermore, in step S2, the mass volume ratio of dinonyl iron, oleic acid and oleylamine is 0.2-0.5 g:450-550 μL:450-550 μL.

[0018] Furthermore, the mass volume ratio of dinonylcarbonyl iron, oleic acid and oleylamine is 0.3 g:500 μL:500 μL.

[0019] Further, the temperature is raised to 200-300°C.

[0020] Furthermore, the temperature was raised to 260°C.

[0021] Further, reflux for 2.5-3.5 h.

[0022] Further, reflux was performed for 3 h.

[0023] Furthermore, washing was performed using a mixed solution of ethanol and n-hexane.

[0024] Furthermore, the volume ratio of ethanol to n-hexane is 5-15:5-15.

[0025] Furthermore, the volume ratio of ethanol to n-hexane is 10:10.

[0026] Furthermore, in step S3, the mass volume ratio of dimercaptobutyric acid, n-hexane and N,N-dimethylamide of tetrafluoroboron nitroso is 0.02-0.04 g: 5-15 mL: 3-7 mL.

[0027] Furthermore, the mass volume ratio of dimercaptobutyric acid, n-hexane and N,N-dimethylamide of tetrafluoroboron nitroso is 0.03 g:10 mL:5 mL.

[0028] Furthermore, the concentration of the hydrophobic ultra-small iron-platinum nanoalloy in the second mixed solution is 0.1-0.2 mg / mL.

[0029] Furthermore, the concentration of the hydrophobic ultrasmall iron-platinum nanoalloy in the mixed solution 2 is 0.1 mg / mL.

[0030] Furthermore, the concentration of N,N-dimethylamide of tetrafluoroborate is 0.5-1.5 mg / mL.

[0031] Furthermore, the concentration of N,N-dimethylamide of tetrafluoroborate was 1 mg / mL.

[0032] Further, after shaking at 150-200 r / min for 45-55 min, the mixture was washed 2-4 times with a mixture of deionized water and ethanol and centrifuged at 12000-16000 r / min.

[0033] Furthermore, after shaking at 170 r / min for 50 min, the mixture was washed three times with a mixture of deionized water and ethanol and centrifuged at 14000 r / min.

[0034] Furthermore, the volume ratio of deionized water to ethanol is 5-15:5-15.

[0035] Furthermore, the volume ratio of ionized water to ethanol is 10:10.

[0036] Furthermore, in step S4, the mass volume ratio of platelet-derived growth factor B chain cyclic peptide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide stirring, amino-containing polyethylene glycol and dimethyl sulfoxide is 4-6 mg:40-60 mg:40-60 mg:15-25 mg:4-6 mL.

[0037] Furthermore, the mass volume ratio of platelet-derived growth factor B chain cyclic peptide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide stirring, amino-containing polyethylene glycol and dimethyl sulfoxide is 5 mg:50 mg:50 mg:20 mg:5 mL.

[0038] Further, the mixture was magnetically stirred at room temperature for 1-3 h, and then stirred at room temperature for 5-7 h.

[0039] Further, the mixture was magnetically stirred at room temperature for 2 h, and then stirred at room temperature for 6 h.

[0040] Furthermore, in step S5, the mass volume ratio of homoharringtonine, soybean lecithin, cholesterol, distearoyl phosphatidylethanolamine, polyethylene glycol-modified platelet-derived growth factor B chain and chloroform is 0.5-1.5 mg: 20-30 mg: 2-6 mg: 3-7 mg: 5-15 mg: 10-20 mL.

[0041] Furthermore, the mass volume ratio of homoharringtonine, soybean lecithin, cholesterol, distearoylphosphatidylethanolamine, polyethylene glycol-modified platelet-derived growth factor B chain and chloroform is 1 mg:25 mg:4 mg:5 mg:10 mg:15 mL.

[0042] Further, rotary evaporation is performed using a rotary evaporator at 35-45°C and 100-150 r / min.

[0043] Furthermore, rotary evaporation was performed using a rotary evaporator at 40°C and 120 r / min.

[0044] Furthermore, in step S6, the mass volume ratio of glucose oxidase, hydrophilic ultrasmall iron-platinum nanoalloy, deionized water and chloroform in step S5 is 2-4 mg: 5-15 mg: 5-15 mL: 10-20 mL.

[0045] Furthermore, the mass volume ratio of glucose oxidase, hydrophilic ultrasmall iron-platinum nanoalloy, deionized water and chloroform in step S5 is 3 mg:10 mg:10 mL:15 mL.

[0046] Further, ultrasonication was performed at 35-45°C for 25-35 min.

[0047] Furthermore, the mixture was ultrasonicated at 40°C for 30 min.

[0048] Furthermore, the solution was extruded using an extruder.

[0049] Furthermore, the nanomaterials were stored at 4 °C.

[0050] The nanomaterial is prepared by the above-mentioned method for preparing the nanomaterial for diabetes combined with colorectal cancer.

[0051] The application of the above nanomaterials in the preparation of drugs for treating diabetes combined with colorectal cancer.

[0052] In summary, the present invention has the following beneficial effects:

[0053] 1. The present invention uses proteomics technology to discover specific targets for diabetes combined with colorectal cancer - aminoacyl tRNA synthetases: AARS, TARS, VARS, and TARS. According to the characteristics of the targets, sensitive drugs are sought: homoharringtonine. Ultra-small FePt nano-alloys are synthesized by high-temperature thermal degradation method to regulate and promote tumor glycolysis process and control blood sugar. Platelet-derived growth factor B chain (PDGFB)-coupled liposomes (PDGFB-liposomes) are prepared by thin film hydration technology to encapsulate ultra-small iron-platinum nano-alloys (FePt alloy), homoharringtonine (HHT) and glucose oxidase (GOx), and a nanomaterial (PDGFB-LFPHG) with targeting, hypoglycemic, drug-loading and high efficiency for diabetes combined with colorectal cancer is prepared. The present invention integrates homoharringtonine, a drug targeting aminoacyl tRNA synthetase, with glucose oxidase, which has a hypoglycemic effect, through nanotechnology to construct a nanomaterial PDGFB-LFPHG with hypoglycemic and synergistic anti-tumor effects. The nanomaterial PDGFB-LFPHG showed strong anti-tumor activity in a model of diabetes combined with colorectal cancer, with a tumor inhibition rate of up to 78.46% in mice with diabetes combined with colorectal cancer, providing a feasible solution for the precise treatment of such T2DM cancer patients.

[0054] 2. The nanomaterial PDGFB-LFPHG prepared by the method provided by the present invention can be used for the treatment of T2DM type diabetes combined with tumors. Its main advantage is that it has a strong synergistic anti-tumor effect. The specific synergistic effects are as follows: Platelet-derived growth factor B chain cyclic peptide can target the delivery of nanomaterials to the colorectal cancer tumor site, and release glucose oxidase, homoharringtonine and iron-platinum nanoalloy in response to the tumor microenvironment. Subsequently, the released glucose oxidase consumes glucose in the hyperglycemic microenvironment and produces a large amount of hydrogen peroxide; the hydrophilic ultra-small iron-platinum nanoalloy can catalyze the Fenton reaction, generate a large amount of cytotoxic hydroxyl radicals, and induce cancer cell death; in addition, the iron-platinum nanoalloy can also regulate the glycolysis process of cancer cells, consume glucose in cancer cells, and cooperate with the released sensitive drug homoharringtonine to efficiently kill tumor cells, realizing synergistic and personalized treatment for diabetes combined with colorectal cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 This is the principal component analysis diagram of specific differentially expressed proteins in diabetes and colorectal cancer;

[0056] Figure 2 This is the result diagram of KEGG signaling pathway enrichment analysis of specific differentially expressed proteins in diabetes and colorectal cancer;

[0057] Figure 3 This is the IC50 value result diagram of HHT on CT26 cells;

[0058] Figure 4 This is the IC50 value result diagram of 5-FU on CT26 cells;

[0059] Figure 5 This is the IC50 value result graph of CDDP on CT26 cells;

[0060] Figure 6 This is a transmission electron microscope image of a hydrophilic ultra-small iron-platinum nanoalloy;

[0061] Figure 7 This is the transmission electron microscopy image of PDGFB-LFPHG nanomaterial;

[0062] Figure 8 This is the transmission electron microscopy image of PDGFB-LFPHG nanomaterial;

[0063] Fig. 9 This is the statistical result diagram of the hydrated particle size of PDGFB-LFPHG nanomaterials;

[0064] Fig.10 This is the infrared spectrum of PDGFB-LFPHG nanomaterials;

[0065] Fig.11Figure 2 shows the results of cell flow cytometry analysis of different nanomaterials;

[0066] Fig.12 Transmission electron microscopy images of PDGFB-LFPHG nanomaterials at different pH values;

[0067] Fig.13 This is a diagram showing the inhibitory effect of PDGFB-LFPHG nanomaterials on tumor cell proliferation. DETAILED DESCRIPTION

[0068] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific conditions are specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.

[0069] Example 1

[0070] A method for preparing a nanomaterial for diabetes combined with colorectal cancer comprises the following steps:

[0071] S1. Dissolve 0.2 g of hexadecanediol and 0.1 g of platinum acetylacetonate in 20 mL of dibenzyl ether, pour into a conical flask, heat to 100°C under nitrogen protection, then add 170 μL of oleic acid and 170 μL of oleylamine and keep warm for 30 min to obtain a mixed solution 1.

[0072] S2, adding 500 μL of oleic acid, 500 μL of oleylamine and 0.3 g of dinonyl iron to the mixed solution 1 obtained in step S1, continuing to heat to 260° C., reflux for 3 h, then cool to room temperature and wash with a mixed solution of ethanol and n-hexane to obtain a hydrophobic ultrasmall iron-platinum nanoalloy;

[0073] S3, dispersing the hydrophobic ultra-small iron-platinum nanoalloy obtained in step S2 in 10 mL of n-hexane to obtain a mixed solution II, wherein the concentration of the hydrophobic ultra-small iron-platinum nanoalloy in the mixed solution II is 0.1 mg / mL, then adding 5 mL of a 1 mg / mL N,N-dimethylamide solution of tetrafluoroboron nitrite, oscillating until a two-phase layer appears on the liquid surface, removing the upper solution, adding 0.03 g of dithiothiobutyric acid, oscillating at 170 r / min for 50 min, washing with a mixed solution of deionized water and ethanol for 3 times, and centrifuging at 14000 r / min to obtain a hydrophilic ultra-small iron-platinum nanoalloy;

[0074] S4, dissolving 5 mg of platelet-derived growth factor B chain cyclic peptide in 5 mL of dimethyl sulfoxide, then adding 50 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and 50 mg of N-hydroxysuccinimide, stirring magnetically at room temperature for 2 h, then adding 20 mg of amino-containing polyethylene glycol, stirring magnetically at room temperature for 6 h, removing unreacted polyethylene glycol and other substances with a dialysis membrane, and obtaining polyethylene glycol-modified platelet-derived growth factor B chain;

[0075] S5, dissolving 1 mg of homoharringtonine, 25 mg of soy lecithin, 4 mg of cholesterol, 5 mg of distearoyl phosphatidylethanolamine and 10 mg of polyethylene glycol-modified platelet-derived growth factor B chain obtained in step S4 in 15 mL of chloroform, and using a rotary evaporator to evaporate the organic solvent in the round-bottom flask at 40° C. and 120 r / min. After the liquid is completely removed, a transparent film is formed at the bottom of the flask, thereby obtaining a platelet-derived growth factor B chain-targeted liposome membrane;

[0076] S6. Dissolve 3 mg of glucose oxidase and 10 mg of the hydrophilic ultrasmall iron-platinum nanoalloy obtained in step S3 in 10 mL of deionized water to obtain a mixed solution three, then add the mixed solution three to the liposome membrane targeted by the platelet-derived growth factor B chain obtained in step S5, and ultrasonicate in a 40°C water bath for 30 min to obtain a nanoliposome initial solution. Use an extruder to extrude the solution, and freeze-dry it to obtain a nanomaterial (PDGFB-LFPHG).

[0077] Example 2

[0078] A method for preparing a nanomaterial for diabetes combined with colorectal cancer comprises the following steps:

[0079] S1. Dissolve 0.1 g of hexadecanediol and 0.05 g of platinum acetylacetonate in 10 mL of dibenzyl ether, pour into a conical flask, heat to 90° C. under nitrogen protection, then add 150 μL of oleic acid and 150 μL of oleylamine and keep warm for 25 min to obtain a mixed solution 1.

[0080] S2, adding 450 μL of oleic acid, 450 μL of oleylamine and 0.2 g of dinonyl iron carbonyl to the mixed solution 1 obtained in step S1, continuing to heat to 200° C., reflux for 2.5 h, then cool to room temperature and wash with a mixed solution of ethanol and n-hexane to obtain a hydrophobic ultrasmall iron-platinum nanoalloy;

[0081] S3, dispersing the hydrophobic ultra-small iron-platinum nanoalloy obtained in step S2 in 5 mL of n-hexane to obtain a mixed solution II, wherein the concentration of the hydrophobic ultra-small iron-platinum nanoalloy in the mixed solution II is 0.1 mg / mL, then adding 7 mL of a 0.5 mg / mL N,N-dimethylamide solution of tetrafluoroboron nitrite, oscillating until a two-phase layer appears on the liquid surface, removing the upper solution, adding 0.02 g of dithiothiobutyric acid, oscillating at 150 r / min for 45 min, washing twice with a mixed solution of deionized water and ethanol, and centrifuging at 12000 r / min to obtain a hydrophilic ultra-small iron-platinum nanoalloy;

[0082] S4, dissolving 4 mg of platelet-derived growth factor B chain cyclic peptide in 4 mL of dimethyl sulfoxide, then adding 40 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and 40 mg of N-hydroxysuccinimide, stirring magnetically at room temperature for 1 hour, then adding 15 mg of amino-containing polyethylene glycol, stirring magnetically at room temperature for 5 hours, removing unreacted polyethylene glycol and other substances with a dialysis membrane, and obtaining polyethylene glycol-modified platelet-derived growth factor B chain;

[0083] S5, dissolving 0.5 mg of homoharringtonine, 20 mg of soy lecithin, 2 mg of cholesterol, 3 mg of distearoyl phosphatidylethanolamine and 5 mg of polyethylene glycol-modified platelet-derived growth factor B chain obtained in step S4 in 10 mL of chloroform, and using a rotary evaporator to evaporate the organic solvent in the round-bottom flask at 35° C. and 100 r / min. After the liquid is completely removed, a transparent film is formed at the bottom of the flask, thereby obtaining a platelet-derived growth factor B chain-targeted liposome membrane;

[0084] S6. Dissolve 2 mg of glucose oxidase and 5 mg of the hydrophilic ultrasmall iron-platinum nanoalloy obtained in step S3 in 5 mL of deionized water to obtain mixed solution three, then add the mixed solution three to the liposome membrane targeted by platelet-derived growth factor B chain obtained in step S5, and ultrasonicate in a 35°C water bath for 25 min to obtain a nanoliposome initial solution. Use an extruder to extrude the solution, and freeze-dry to obtain a nanomaterial.

[0085] Example 3

[0086] A method for preparing a nanomaterial for diabetes combined with colorectal cancer comprises the following steps:

[0087] S1. Dissolve 0.3 g of hexadecanediol and 0.15 g of platinum acetylacetonate in 30 mL of dibenzyl ether, pour into a conical flask, heat to 110° C. under nitrogen protection, then add 200 μL of oleic acid and 200 μL of oleylamine and keep warm for 35 min to obtain a mixed solution 1.

[0088] S2, adding 550 μL of oleic acid, 550 μL of oleylamine and 0.5 g of dinonyl iron to the mixed solution 1 obtained in step S1, continuing to heat to 300° C., reflux for 3.5 hours, then cool to room temperature and wash with a mixed solution of ethanol and n-hexane to obtain a hydrophobic ultrasmall iron-platinum nanoalloy;

[0089] S3, dispersing the hydrophobic ultra-small iron-platinum nanoalloy obtained in step S2 in 15 mL of n-hexane to obtain a mixed solution II, wherein the concentration of the hydrophobic ultra-small iron-platinum nanoalloy in the mixed solution II is 0.2 mg / mL, then adding 7 mL of a 1.5 mg / mL N,N-dimethylamide solution of tetrafluoroboron nitrite, oscillating until a two-phase layer appears on the liquid surface, removing the upper solution, adding 0.04 g of dithiothiobutyric acid, oscillating at 200 r / min for 55 min, washing with a mixed solution of deionized water and ethanol for 4 times, and centrifuging at 16000 r / min to obtain a hydrophilic ultra-small iron-platinum nanoalloy;

[0090] S4, dissolving 6 mg of platelet-derived growth factor B chain cyclic peptide in 6 mL of dimethyl sulfoxide, then adding 60 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and 60 mg of N-hydroxysuccinimide, stirring magnetically at room temperature for 3 h, then adding 25 mg of amino-containing polyethylene glycol, stirring magnetically at room temperature for 7 h, removing unreacted polyethylene glycol and other substances with a dialysis membrane, and obtaining polyethylene glycol-modified platelet-derived growth factor B chain;

[0091] S5, dissolving 1.5 mg of homoharringtonine, 30 mg of soy lecithin, 6 mg of cholesterol, 7 mg of distearoyl phosphatidylethanolamine and 15 mg of the polyethylene glycol-modified platelet-derived growth factor B chain obtained in step S4 in 20 mL of chloroform, and using a rotary evaporator to evaporate the organic solvent in the round-bottom flask at 45° C. and 150 r / min. After the liquid is completely removed, a transparent film is formed at the bottom of the flask, thereby obtaining a platelet-derived growth factor B chain-targeted liposome membrane;

[0092] S6. Dissolve 4 mg of glucose oxidase and 15 mg of the hydrophilic ultrasmall iron-platinum nanoalloy obtained in step S3 in 15 mL of deionized water to obtain mixed solution three, then add the mixed solution three to the liposome membrane targeted by platelet-derived growth factor B chain obtained in step S5, and ultrasonicate in a water bath at 35°C for 25 min to obtain a nanoliposome initial solution. Use an extruder to extrude the solution, and freeze-dry to obtain a nanomaterial.

[0093] Experimental Example 1 Determination of disease-specific targets

[0094] Selection criteria for the colorectal cancer group: (1) Meet the 2020 diagnostic criteria for colorectal cancer; (2) Have not received any anti-tumor drug treatment or chemotherapy before surgery; (3) Have no damage to important organs such as the heart, liver, lung, kidney, and brain.

[0095] Exclusion criteria for the colorectal cancer group: (1) patients who did not meet the diagnostic criteria for CRC; (2) patients who had concurrently suffered from other malignant tumors; (3) patients who were pregnant or had mental illness; (4) patients with a history of heart, liver, kidney, lung, or hematopoietic system damage.

[0096] Diagnostic criteria for T2DM: (1) Those who have been diagnosed with diabetes; (2) Those who have symptoms of diabetes and the first fasting plasma blood glucose (FBG) ≥ 7.0 mM or the random blood glucose or 2 h blood glucose after an oral glucose tolerance test (2hPG) ≥ 11.1 mM; (3) If there are no typical symptoms of diabetes, the above monitoring needs to be repeated on another day. If any of the above three criteria are met, the patient is diagnosed with diabetes.

[0097] 1. Tissue protein sample extraction

[0098] The selected cancer and adjacent cancer tissues were taken out from the -80℃ refrigerator and placed on a plate to thaw. 35 mg of each sample was placed in a tissue grinder and fully ground into portions in 1.5 mL centrifuge tubes. The tubes were labeled and 100 μL of the prepared lysis buffer containing the cocktail was added. The ground tissues were further broken up using an ultrasonic cell disruptor.

[0099] 2. Mass spectrometry sample preparation

[0100] (1) Peptide extraction: According to the measured sample concentration, aspirate the sample so that the total protein content is 20 mg (it is best to adjust the protein concentration to 1 μg / μL, 20 μL). Then add 1 μL of DTT to each sample, mix it thoroughly, and centrifuge it. Place it at 50°C for 15 minutes, then add 1 μL of IAA to each tube, incubate it at room temperature in the dark for 15 minutes, then add 4 times the liquid content of the tube to each tube. Digestion buffer is added to each tube, shake and mix thoroughly, and centrifuge it. Then add 2 μL of trypsin to each tube, mix thoroughly, centrifuge it, place it at 37°C for 16 hours, and finally add 37 μL of sample buffer to each tube.

[0101] (2) Peptide purification: In order to remove the salt components in the sample, add 200μL activation solution to the C18 column, centrifuge at room temperature, 1400×G for 30s, discard the liquid, and repeat twice. After removing the supernatant, add 200μL equilibration solution. Centrifuge twice under the same conditions. Then put the C18 column into a 2mL EP tube, and wash the sample repeatedly in the same way as before. Continue to add 200μL equilibration solution for washing, and repeat the centrifugation conditions twice. Finally, transfer the C18 column to a new 1.5mL centrifuge tube, add the extract solution, centrifuge again at room temperature, 1400×G for 1min, take the supernatant, dry the sample, and store it in a -80℃ refrigerator for later use.

[0102] 3. Mass spectrometry analysis

[0103] The sample was dissolved in 0.1vt% formic acid solution and loaded, and the peptides were separated using EASY-nLC1000 liquid chromatography (Thermo Fisher Scientific, Germany), and then the peptides were dissociated into ions and entered the Orbitrap ion trap orbit for mass spectrometry analysis. The original mass spectrometry data were searched and compared in the UniProtHomo sapiens database using Maxquant (version 1.5.0.1) software.

[0104] 4. Bioinformatics analysis

[0105] (1) Determination of differentially expressed proteins: To analyze the differences in protein expression among the groups, proteins that met the conditions of P < 0.05 and |log2 fold change|(|log2 FC|) > 1 were identified as differentially expressed proteins.

[0106] (2) Function and pathway enrichment analysis: The differentially expressed proteins were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment using an online tool called Web Gestalt (http: / / webgestalt.org) and Gene Ontology (http: / / pantherdb.org / ). At the same time, the information in the KEGG analysis was visualized using the online tool Bioinformatics (http: / / www.bioinformatics.com.cn / login / ). The results are shown in Figure 2. Figure 1 and Figure 2 shown.

[0107] Depend on Figure 1 It can be seen that principal component analysis (PCA) showed that there was a significant separation between diabetes and colorectal cancer tissues and normal colon mucosa tissues. However, there was no significant difference between tumors or normal mucosa, and between diabetic and non-diabetic patients.

[0108] Depend on Figure 2 It can be seen that the KEGG pathway enrichment score shows the clustering of 10 metabolic pathways. Renin-angiotensin system, pathogenic Escherichia coli infection, aminoacyl-tRNA biosynthesis, gap junction and proteasome are the top five metabolic dysregulation pathways in colorectal cancer and diabetes. In patients with colorectal cancer and diabetes, the aminoacyl-tRNA biosynthesis pathway is significantly upregulated. This also lays a theoretical foundation for the selection of drugs that target the aminoacyl-tRNA biosynthesis pathway and inhibit protein synthesis.

[0109] Experimental Example 2 Screening of Sensitive Drugs for Malignant Tumors

[0110] (1) CT26 cells were seeded at a density of 8000 cells / well in a 96-well plate, and 1640 complete medium with 1 mg / mL and 2 mg / mL glucose concentrations were added, respectively, and cultured at 37°C and 5% CO2 for 24 h;

[0111] (2) The concentration gradient of homoharringtonine (HHT) was set to 25, 50, 100, 200, 400, 800 nM; the concentration gradient of 5-fluorouracil (5-FU) was set to 5, 10, 20, 40, 80, 160, 320 μM; the concentration gradient of cisplatin (CDDP) was set to 10, 20, 40, 80, 160, 320 μM, and 6 replicate wells were set for each concentration. After 48 hours of treatment, the drug-added culture medium was discarded and CCK8 / DMEM (1:9, 200 μL) was added to each well. After incubation in the dark for 2 hours, the cell viability was determined by an ELISA instrument, and the IC50 values ​​of the three chemotherapy drugs, homoharringtonine, 5-fluorouracil and cisplatin, on CT26 cells were determined. The results are as follows: Figure 3-Figure 5 shown.

[0112] Depend on Figure 3-Figure 5 It can be seen that the IC50 of CT26 cells to HHT, 5-FU, and CDDP under low glucose conditions are 84.01nM, 4207μM, and 19.21μM, respectively. Under high glucose conditions, the IC50 of HHT, 5-FU, and CDDP are 78.36nM, 4348μM, and 19.61μM, respectively. Therefore, CT26 cells are more sensitive to HHT drugs, and the sensitivity is higher under high glucose conditions.

[0113] Experimental Example 3 Preparation of Hydrophilic Ultra-Small Iron-Platinum Nanoalloy

[0114] 1. A method for preparing a hydrophilic ultra-small iron-platinum nanoalloy comprises the following steps:

[0115] (1) 0.1 g of platinum acetylacetonate, 1,0.2 g of 2-hexadecanediol and 20 mL of dibenzyl ether were poured into a three-necked round-bottom flask and heated to 100 °C under nitrogen protection to form a uniform solution. Subsequently, 170 μL of oleic acid and 170 μL of oleylamine were added and maintained for 30 min.

[0116] (2) further adding 500 μL of oleic acid and 500 μL of oleylamine, followed by adding 0.3 g of dinonyl iron, setting the temperature to 260° C., heating under reflux for 3 h. After the reaction is completed, the reaction system is cooled to room temperature, washed with a mixture of ethanol and n-hexane, and the hydrophobic ultrasmall iron-platinum nanoalloy is collected;

[0117] (3) 0.1 mg of iron-platinum nanoalloy was dispersed in 10 mL of n-hexane, and 5 mL of 1 mg / mL tetrafluoroboron nitrite in N,N-dimethylamide (DMF) solution was added. The mixture was shaken vigorously until two phases appeared on the liquid surface, and the upper layer was clear n-hexane. The upper layer was removed. Subsequently, 0.03 g of dithiothiobutyric acid (DMSA) was added to the solution. After shaking for 50 min at 170 r / min, the mixture was washed three times with a mixture of deionized water and ethanol, and centrifuged at 14000 r / min. The hydrophilic iron-platinum nanoalloy (FePt) was collected, dispersed in water, and stored at 4°C.

[0118] 2. Observation of hydrophilic ultra-small iron-platinum nanoalloy

[0119] The morphology of the hydrophilic ultra-small FePt nanoalloy (FePt) prepared above was observed, and the transmission electron microscopy (TEM) results are as follows: Figure 6 shown.

[0120] Depend on Figure 6 It can be seen that the size of the nanoparticles is about 2 nm, and the morphology is uniform and the monodispersity is good. Experimental Example 4 Preparation of PDGFB-LFPHG Nanomaterials

[0121] 1. A method for preparing PDGFB-LFPHG nanomaterials, comprising the following steps:

[0122] (1) Preparation of PDGFB-coupled polyethylene glycol: 5 mg of platelet-derived growth factor B chain (PDGFB) cyclic peptide was dissolved in 5 mL of dimethyl sulfoxide (DMSO), and 50 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 50 mg of N-hydroxysuccinimide (NHS) were further added to the solution. After magnetic stirring at room temperature for 2 h, 20 mg of amino-containing polyethylene glycol (PEG-NH2) was added to the reaction system, and the magnetic stirring reaction was continued at room temperature for 6 h. Subsequently, the unreacted polyethylene glycol and other substances were removed by dialysis membrane, and the product in the dialysis bag was collected to obtain PDGFB-coupled polyethylene glycol (PEG-PDGFB).

[0123] (2) Preparation of PDGFB-targeted liposome membrane: 1 mg homoharringtonine (HHT), 25 mg soybean lecithin, 10 mg PDGFB-coupled polyethylene glycol (PEG-PDGFB), 4 mg cholesterol and 5 mg distearoyl phosphatidylethanolamine were dissolved in 15 mL chloroform solution, and the solution was transferred to a round-bottom flask to form a uniform transparent solution. The organic solvent in the round-bottom flask was evaporated by rotary evaporation at 40°C and 120 r / min. After the liquid was completely removed, a transparent film was formed at the bottom of the flask. Subsequently, 3 mg glucose magnesium oxide (GOx) and 10 mg hydrophilic ultrasmall iron platinum nanoalloy (FePt) were dissolved in 10 mL deionized water, poured into the above round-bottom flask, and placed in a water bath at 40°C. After intense ultrasonication for 30 min, a nanoliposome initial solution was prepared. The solution was further extruded using an extruder to prepare PDGFB-LFPHG nanomaterials, which were freeze-dried to form a nanomaterial dry powder preparation.

[0124] 2. Observation of PDGFB-LFPHG nanomaterials

[0125] The morphology of the prepared PDGFB-LFPHG nanomaterials was characterized by TEM. Figure 7 (Scale bar = 100 nm) and Figure 8 The hydrated particle size of PDGFB-LFPHG nanomaterials was detected by laser dynamic light scattering nanoparticle size analyzer. Fig. 9 As shown. The components of PDGFB-LFPHG nanomaterials were characterized by infrared spectrometer, as shown Fig.10 shown.

[0126] Depend on Figure 7 and Figure 8 It can be seen that the nanomaterials are in the form of aggregated particles with uniform morphology and a size of about 60nm.

[0127] Depend on Fig. 9 It can be seen that the hydrated particle size of the nanomaterial is about 200nm and the dispersibility is good.

[0128] Depend on Fig.10 It can be seen that after structural and compound modification, the nanomaterial PDGFB-LFPHG exhibits characteristic absorption peaks corresponding to compounds such as HHT, GOx, and FePt, proving the successful preparation of the nanomaterial PDGFB-LFPHG.

[0129] Experimental Example 5 Evaluation of tumor targeting ability of PDGFB-LFPHG

[0130] (1) Culture of tumor cells

[0131] CT26 cells were cultured at 1×10 5The cells were inoculated at a density of 1000 / dish in a confocal dish and cultured for 12 h in 1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin double antibody.

[0132] (2) Monitoring of nanoparticle uptake by tumor cells

[0133] Using the same thin film hydration technique, FePt, HHT and GOx were encapsulated in conventional liposomes without PDGFB coupling to prepare non-targeted nanomaterials (LFPHG) as experimental controls.

[0134] The prepared LFPHG and nanomaterial PDGFB-LFPHG were labeled with fluorescein isothiocyanate and then co-cultured with CT26 cancer cells at a concentration of 40 μg / mL. After 6 hours, CT26 cancer cells were collected for cell flow cytometry analysis to monitor the uptake of the two nanomaterials by CT26 cancer cells. Fig.11 As shown, Fig.11 In the figure, the upper figure shows the result of LFPHG, and the lower figure shows the result of PDGFB-LFPHG.

[0135] Depend on Fig.11 It can be seen that compared with cancer cells incubated with LFPHGt, tumor cells incubated with PDGFB-LFPHG nanomaterials have higher FITC fluorescence signals, which indicates that the nanomaterials labeled with PDGFB cyclic peptide have targeting properties for CT26 cancer cells, allowing them to take up more nanomaterials.

[0136] Test Example 6 Evaluation of PDGFB-LFPHG Acid Responsiveness

[0137] PDGFB-LFPHG was dispersed in phosphate buffer solutions with pH values ​​of 7.4, 6.5 and 5.5, respectively, and incubated in a shaker at 37°C and 170 rpm for 12 h. The transmission electron microscopy (TEM) results are shown in Figure 2. Fig.12 As shown, Fig.12 In the figure, from top to bottom and from left to right, they are the TEM results of PDGFB-LFPHG nanomaterials at pH values ​​of 7.4, 5.5, and 4.5.

[0138] Depend on Fig.12 It can be seen that as the pH decreases, the structural disintegration of the PDGFB-LFPHG nanomaterial is accelerated, which proves that the structure of the nanomaterial has the characteristics of low pH response collapse.

[0139] Experimental Example 7 Anti-tumor Effect of PDGFB-LFPHG

[0140] (1) Culture of tumor cells

[0141] 10 4CT26 cells were seeded in a 96-well plate at a density of 100 cells / well and cultured for 12 hours with 1640 medium containing 1 mg / mL and 2 mg / mL glucose, respectively. After 12 hours, the cells were incubated with different concentrations of materials for 24 hours.

[0142] (2) MTT assay to detect the inhibitory effect of PDGFB-LFPHG on tumor cell proliferation

[0143] The culture medium of the 96-well plate was removed, and a solution of culture medium and MTT in a ratio of 9:1 was added to each well. After incubation in the incubator for 4 hours, the liquid was removed, and 250 μL of dimethyl sulfoxide solution was added to each well. After gently shaking, the plate was detected at 490 nm using an enzyme-labeled instrument. The results are as follows: Fig.13 shown.

[0144] Depend on Fig.13 It can be seen that the MTT results showed that PDGFB-LFPHG had a concentration-dependent growth inhibitory effect on CT26 tumor cells, and the effect was stronger at high glucose levels.

[0145] Experimental Example 8 Evaluation of the tumor inhibition rate of PDGFB-LFPHG nanomaterials on normal blood sugar mice

[0146] Male Bal b / c mice were injected subcutaneously with CT26 (1×10 5 ) cells to establish a CT26 tumor model. After inoculation, the tumor volume was monitored and the tumor volume was about 80 mm 3 In vivo experiments were started at 4 pm. Tumor-bearing mice were randomly divided into 6 groups (n≥4): (a) PBS, (b) HHT, (c) GOx, (d) FePt, (e) LFPHG, and (f) PDGFB-LFPHG. The mice were injected with drugs (equivalent to Pt: 2 mg / kg) through the tail vein every two days, and the body weight and tumor volume of the mice were recorded every other day. The fasting blood glucose of the mice was measured every 7 days. The mice were killed on the 15th day, and their main organs and tumor tissues were removed for histological analysis. The data are shown in Table 1.

[0147] Table 1 Tumor inhibition rate of different samples on normal blood sugar mice

[0148]

[0149]

[0150] As shown in Table 1, the tumor inhibition rate of PDGFB-LFPHG nanomaterials on normal blood sugar mice can be as high as 71.77%.

[0151] Experimental Example 9 Evaluation of the tumor inhibition rate of PDGFB-LFPHG nanomaterials on diabetic mice with colorectal cancer

[0152] Male Balb / c mice aged 4 weeks were fed with normal diet and water for one week, and then switched to high-fat diet for 8 weeks. After the 8th week, the fasting blood glucose and glucose tolerance of mice were measured. After that, mice that had fasted for 12 hours were intraperitoneally injected with a small dose of STZ (35 mg / kg) for three consecutive days to induce hyperglycemia in mice. One week after the injection, the fasting blood glucose and glucose tolerance of mice were measured again. If the fasting blood glucose was higher than 7.0 mM and the blood glucose level of mice after 2 hours of OGTT was higher than 11.1 mM, the model was successfully established. If the blood glucose level was lower than the judgment standard, STZ was injected again until the blood glucose level reached the diabetic blood glucose standard.

[0153] Based on the established male Bal b / c diabetic mouse model, CT26 (1×10 5 ) cells to establish a CT26 tumor model. When the tumor volume was about 80 mm3, the CT26 tumor-bearing mice were randomly divided into 6 groups (n≥4): (a) PBS, (b) HHT, (c) GOx, (d) FePt, (e) LFPHG, (f) PDGFB-LFPHG. The mice were injected with these drugs or materials (Pt: 2 mg / kg) through the tail vein. The body weight and tumor volume of the mice were recorded every other day, and the fasting blood glucose of the mice was measured every 7 days. The mice were killed on the 15th day, and their main organs and tumor tissues were removed for histological analysis. The data are shown in Table 2.

[0154] Table 2 Tumor inhibition rate of different samples in T2DM combined with CRC mice

[0155]

[0156]

[0157] As shown in Table 2, the tumor inhibition rate of the nanomaterial PDGFB-LFPHG on diabetic mice with colorectal cancer was as high as 78.46%.

[0158] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing nanomaterials for diabetes combined with colorectal cancer, characterized in that: The following steps are involved: S1, dissolving hexadecanediol and platinum acetylacetonate in dibenzyl ether, heating under nitrogen protection, then adding oleic acid and oleylamine and keeping warm to obtain a mixed solution 1; S2, adding oleic acid, oleylamine and dinonyl iron to the mixed solution 1 obtained in step S1, continuing to heat, cooling to room temperature after reflux and washing, to obtain a hydrophobic ultra-small iron-platinum nanoalloy; S3, dispersing the hydrophobic ultra-small iron-platinum nanoalloy obtained in step S2 in a n-hexane solution to obtain a mixed solution II, then adding a solution of tetrafluoroboron nitrite in N,N-dimethylamide, shaking until a two-phase layer appears on the liquid surface, removing the upper solution, and then adding dithiothiobutyric acid, shaking, washing and centrifuging to obtain a hydrophilic ultra-small iron-platinum nanoalloy; S4, dissolving the platelet-derived growth factor B chain cyclic peptide in dimethyl sulfoxide, then adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and N-hydroxysuccinimide and stirring, then adding amino-containing polyethylene glycol and continuing to stir, removing impurities, and obtaining polyethylene glycol-modified platelet-derived growth factor B chain; S5, dissolving homoharringtonine, soybean lecithin, cholesterol, distearoyl phosphatidylethanolamine and the polyethylene glycol-modified platelet-derived growth factor B chain obtained in step S4 in chloroform, and removing the organic solvent after rotary evaporation to obtain a platelet-derived growth factor B chain-targeted liposome membrane; S6. Dissolve glucose oxidase and the hydrophilic ultrasmall iron-platinum nanoalloy obtained in step S3 in deionized water to obtain mixed solution three, then add the mixed solution three to the liposome membrane targeted by platelet-derived growth factor B chain obtained in step S5, and after water bath sonication, obtain a nanoliposome initial solution, extrude the solution, and freeze-dry to obtain a nanomaterial.

2. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S1, the mass volume ratio of hexadecanediol, platinum acetylacetonate, dibenzyl ether, oleic acid and oleylamine is 0.1-0.3 g:0.05-0.15 g:10-30 mL:150-200 μL:150-200 μL.

3. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S2, the mass volume ratio of the dinonylcarbonyl iron, oleic acid and oleylamine is 0.2-0.5 g:450-550 μL:450-550 μL.

4. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S3, the mass volume ratio of the dimercaptobutyric acid, n-hexane and N,N-dimethylamide of tetrafluoroboron nitroso is 0.02-0.04 g: 5-15 mL: 3-7 mL.

5. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S3, the concentration of the hydrophobic ultra-small iron-platinum nanoalloy in the second mixed solution is 0.1-0.2 mg / mL, and the concentration of the N,N-dimethylamide of tetrafluoroboron nitrite is 0.5-1.5 mg / mL.

6. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S4, the mass volume ratio of the platelet-derived growth factor B chain cyclic peptide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide stirring, amino-containing polyethylene glycol and dimethyl sulfoxide is 4-6 mg:40-60 mg:40-60 mg:15-25 mg:4-6 mL.

7. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S5, the mass volume ratio of homoharringtonine, soybean lecithin, cholesterol, distearoyl phosphatidylethanolamine, polyethylene glycol-modified platelet-derived growth factor B chain and chloroform is 0.5-1.5 mg: 20-30 mg: 2-6 mg: 3-7 mg: 5-15 mg: 10-20 mL.

8. The method for preparing a nanomaterial for diabetes combined with colorectal cancer according to claim 1, characterized in that: In step S6, the mass volume ratio of the glucose oxidase, the hydrophilic ultrasmall iron-platinum nanoalloy, the deionized water and the chloroform in step S5 is 2-4 mg: 5-15 mg: 5-15 mL: 10-20 mL.

9. A nanomaterial prepared by the method for preparing a nanomaterial for diabetes combined with colorectal cancer as described in any one of claims 1 to 8.

10. Use of the nanomaterial according to claim 9 in the preparation of a drug for treating diabetes combined with colorectal cancer.